Literature DB >> 12839273

Endothelins in chronic diabetic complications.

Zia Ali Khan1, Subrata Chakrabarti.   

Abstract

Endothelins are widely distributed in the body and perform several vascular and nonvascular functions. Experimental data indicate abnormalities of the endothelin system in several organs affected in chronic diabetic complications. In support of this notion, it has been shown that endothelin-receptor antagonists prevent structural and functional abnormalities in target organs of diabetic complications in animal models. Alterations of plasma endothelin levels have also been demonstrated in human diabetes. This review discusses the role of endothelins in the pathogenesis of chronic diabetic complications. The current experimental evidence suggests that endothelin-receptor antagonism may potentially be an adjuvant therapeutic tool in the treatment of chronic diabetic complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839273     DOI: 10.1139/y03-053

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  23 in total

Review 1.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

2.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

3.  Glucose-induced Akt1 activation mediates fibronectin synthesis in endothelial cells.

Authors:  X Xin; Z A Khan; S Chen; S Chakrabarti
Journal:  Diabetologia       Date:  2005-09-29       Impact factor: 10.122

4.  Glucose-induced up-regulation of CD36 mediates oxidative stress and microvascular endothelial cell dysfunction.

Authors:  H Farhangkhoee; Z A Khan; Y Barbin; S Chakrabarti
Journal:  Diabetologia       Date:  2005-05-25       Impact factor: 10.122

5.  Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.

Authors:  Mohammed Abdelsaid; Handong Ma; Maha Coucha; Adviye Ergul
Journal:  Life Sci       Date:  2014-01-13       Impact factor: 5.037

6.  Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.

Authors:  Alex K Harris; Mostafa M Elgebaly; Weiguo Li; Kamakshi Sachidanandam; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-02-20       Impact factor: 3.619

7.  Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.

Authors:  Kamakshi Sachidanandam; Mostafa M Elgebaly; Alex K Harris; Jim R Hutchinson; Erin M Mezzetti; Vera Portik-Dobos; Adviye Ergul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-04-18       Impact factor: 4.733

8.  Diabetes-mediated middle cerebral artery remodeling is restored by linagliptin: Interaction with the vascular smooth muscle cell endothelin system.

Authors:  Abdul Yasir; Trevor Hardigan; Adviye Ergul
Journal:  Life Sci       Date:  2016-03-02       Impact factor: 5.037

9.  Impaired insulin-mediated vasorelaxation in a nonobese model of type 2 diabetes: role of endothelin-1.

Authors:  Mostafa M Elgebaly; Aisha Kelly; Alex K Harris; Hazem Elewa; Vera Portik-Dobos; Pimonrat Ketsawatsomkron; Mario Marrero; Adviye Ergul
Journal:  Can J Physiol Pharmacol       Date:  2008-06       Impact factor: 2.273

10.  Metallothionein rescues hypoxia-inducible factor-1 transcriptional activity in cardiomyocytes under diabetic conditions.

Authors:  Wenke Feng; Yuehui Wang; Lu Cai; Y James Kang
Journal:  Biochem Biophys Res Commun       Date:  2007-06-19       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.